Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

BioCryst Pharmaceuticals (BCRX) is acquiring Astria Therapeutics (ATXS) for approximately $700 million, or $13 per share, representing a 53% premium, which caused ATXS shares to rally 37.1%. This strategic acquisition, anticipated to close in Q1 2026, will integrate Astria's lead asset, navenibart—a long-acting plasma kallikrein inhibitor for hereditary angioedema (HAE)—into BioCryst's pipeline, strengthening its HAE market position with a differentiated injectable therapy. BioCryst expects the deal to drive double-digit revenue growth, maintain profitability, and be accretive to its non-GAAP operating profit post-launch by leveraging its established commercial platform.

Analysis

BioCryst Pharmaceuticals (BCRX) is acquiring Astria Therapeutics (ATXS) for approximately $700 million, or $13 per share, representing a significant 53% premium over ATXS’s closing price on October 13, 2025. This news prompted a 37.1% rally in ATXS shares, with the definitive agreement anticipated to close in the first quarter of 2026.

The strategic acquisition aims to bolster BCRX’s leadership in the hereditary angioedema (HAE) market by integrating ATXS’s lead asset, navenibart. Navenibart, a long-acting plasma kallikrein inhibitor, offers a highly differentiated administration schedule (every three or six months), addressing a critical unmet need for less frequent dosing in HAE prophylaxis.

BCRX plans to leverage its established commercial platform and existing HAE therapy, Orladeyo, to create a comprehensive treatment suite, expanding patient reach. Financially, the transaction is projected to drive double-digit revenue growth, maintain profitability, and generate positive cash flow, becoming accretive to non-GAAP operating profit in the first full year post-launch of navenibart, which has Phase III data expected in early 2027.

Key Decisions for Investors

• ATXS shareholders should evaluate the tender offer price of $13 per share against current market prices and the anticipated Q1 2026 closing, considering potential arbitrage opportunities or holding until completion.
• BCRX investors should assess the long-term growth potential from the expanded HAE pipeline and the projected financial accretion, while closely monitoring navenibart's Phase III results expected in early 2027 and its subsequent regulatory and commercialization success.
• Investors should consider the competitive landscape in the HAE market and BioCryst's execution risk in integrating Astria's assets and effectively launching navenibart to achieve projected synergies and market penetration.